Jump to section
Sensyne Health's mission is to provide both a financial return to health systems via equity and/or a share in revenues, and a patient outcome 'return' advancing care delivery and disease research and development.
Sensyne Health uses artificial intelligence to develop medical products and services, with a focus on discovering new medicines and improving patient care across the NHS. Sensyne analyses patients’ anonymous genetic data using the company’s clinical AI tech with the aim of accelerating medical research and improving patient care.
It has already partnered with a number of NHS trusts. The company aims to cement its relationships with NHS Trust partners as it builds out the platform and accelerates its capability to support the life sciences industry in driving value from real-world patient data.
A recent shift in leadership appointed Alex Snow as CEO, with the expectation that his experience in life sciences AI and capital-raising credentials will be invaluable to lead Sensyne through the next stage of its development.
Kirsty
Company Specialist at Welcome to the Jungle
Alex Snow
(CEO)An experienced entrepreneur with extensive, executive leadership and a proven track record in AI drug discovery. Founder and CEO of Evolution Group, a UK mid-market investment banking and wealth management group sold to Investec Bank.
Joined as Group Financial Controller. Promoted to Corporate Finance Director after 4 years.